Last reviewed · How we verify

Isoamyl Methoxycinnamate (AMILOXATE)

FDA-approved active Small molecule ✓ Verified May 2026 Quality 6/100

Isoamyl Methoxycinnamate (generic name: AMILOXATE) is a amiloxate drug. It is currently FDA-approved.

Isoamyl Methoxycinnamate is a small molecule used as a sunscreen filter. It has been studied in clinical trials for conditions such as dermatitis and photocontact.

At a glance

Generic nameAMILOXATE
Drug classamiloxate
ModalitySmall molecule
Therapeutic areaOncology
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Isoamyl Methoxycinnamate

What is Isoamyl Methoxycinnamate?

Isoamyl Methoxycinnamate (AMILOXATE) is a amiloxate drug.

What is the generic name of Isoamyl Methoxycinnamate?

AMILOXATE is the generic (nonproprietary) name of Isoamyl Methoxycinnamate.

What drug class is Isoamyl Methoxycinnamate in?

Isoamyl Methoxycinnamate belongs to the amiloxate class. See all amiloxate drugs at /class/amiloxate.

What development phase is Isoamyl Methoxycinnamate in?

Isoamyl Methoxycinnamate is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing